Chimerix Inc (STU:CXF)
€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Chimerix Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 08:00PM GMT
Release Date Price: €1.78 (-0.06%)
Unidentified Analyst

Good morning, and welcome to the last day of the 41st Annual JPMorgan Healthcare Conference. My name is Dave Parag, and I'm an associate part of the JPMorgan Health Care Investment Banking team.

Today, I have the pleasure of introducing Chimerix and their CEO, Mike Sherman. In the audience, we also have CTO, Dr. Joshua Allen; and CFO and CBO, Mike Andriole. Please note, there will be time for Q&A at the end of the session. A mic will be passed around for any questions that you have. Thank you, and take it away. Mike.

Michael A. Sherman
Chimerix, Inc. - CEO, President & Director

Thanks, Dave. It's great to be here back in person again. It's especially energizing when you've got some exciting things to talk about. So I'd love to take the opportunity to give you an update.

For those that don't know, Chimerix is an oncology-focused company headquartered in the Research Triangle in North Carolina and have a Phase III program and a mutant form of glioma that we're really excited about the data we've generated there and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot